Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, WuXi Biologics (Cayman)'s average EPS without NRIGrowth Rate was 22.80% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 5.20% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 19.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 49.00% per year.
During the past 12 years, WuXi Biologics (Cayman)'s highest 3-Year average EPS without NRI Growth Rate was 138.10% per year. The lowest was 5.20% per year. And the median was 55.80% per year.
WuXi Biologics (Cayman) (OTCPK:WXIBF) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
WuXi Biologics (Cayman) Earnings per Share (Diluted) Related Terms
WuXi Biologics (Cayman) Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) Earnings per Share (Diluted) Chart
WXIBF vs VRTX, REGN, RVMD: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PE Ratio distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s PE Ratio falls into.
WuXi Biologics (Cayman) Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
WuXi Biologics (Cayman)'s Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $0.16 mean?
WuXi Biologics (Cayman) (WXIBF) has a Earnings per Share (Diluted) of $0.16 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #754 out of 1162 companies in the Biotechnology industry, placing it in the top 64.9%.
Is WuXi Biologics (Cayman)'s Earnings per Share (Diluted) too high?
WuXi Biologics (Cayman)'s current Earnings per Share (Diluted) is $0.16. The Biotechnology industry median Earnings per Share (Diluted) is 16.20. WuXi Biologics (Cayman)'s value of $0.16 is 99% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #754 out of 1162 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 98/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #754 out of 1162 companies for Earnings per Share (Diluted). This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. WuXi Biologics (Cayman)'s value of $0.16 is 99% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Earnings per Share (Diluted) of $0.16 is 99% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Earnings per Share (Diluted) is $0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.31, compared to a current price of $6.45 — trading 21.5% above its estimated fair value. The current Earnings per Share (Diluted) is $0.16 and 99% below the Biotechnology industry median of 16.20. WuXi Biologics (Cayman)'s overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Earnings per Share (Diluted) is $0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be overvalued.
The current stock price of $6.45 is trading 21.5% above its estimated GF Value™ of $5.31.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Overvalued.
Key valuation signals for WXIBF:
Earnings per Share (Diluted): $0.16
GF Value™: $5.31 vs. price of $6.45 (21.5% above fair value)
Industry Position: 99% below the Biotechnology median (#754 of 1162)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
98GF Score
Get the complete analysis for WXIBF
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
